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Background: Interferon-γ (IFN-γ) or interleukin-4 (IL-4) drives widely different tran-
scriptional programs in macrophages. However, how IFN-γ and IL-4 alter expression 
of histone-modifying enzymes involved in epigenetic regulation and how this affects the 
resulting phenotypic polarization is incompletely understood.
Methods and results: We investigated steady-state messenger RNA levels of 84 
histone-modifying enzymes and related regulators in colony-stimulating factor-1 differ-
entiated primary human macrophages using quantitative polymerase chain reaction. 
IFN-γ or IL-4 treatment for 6–48 h changed 11 mRNAs significantly. IFN-γ increased 
CIITA, KDM6B, and NCOA1, and IL-4 also increased KDM6B by 6 h. However, either 
cytokine decreased AURKB, ESCO2, SETD6, SUV39H1, and WHSC1, whereas IFN-γ 
alone decreased KAT2A, PRMT7, and SMYD3 mRNAs only after 18 h, which coincided 
with decreased cell proliferation. Rendering macrophages quiescent by growth factor 
starvation or adenovirus-mediated overexpression of p27kip1 inhibited expression of 
AURKB, ESCO2, SUV39H1, and WHSC1, and mRNA levels were restored by overex-
pressing the S-phase transcription factor E2F1, implying their expression, at least partly, 
depended on proliferation. However, CIITA, KDM6B, NCOA1, KAT2A, PRMT7, SETD6, 
and SMYD3 were regulated independently of effects on proliferation. Silencing KDM6B, 
the only transcriptional activator upregulated by both IFN-γ and IL-4, pharmacologically 
or with short hairpin RNA, blunted a subset of responses to each cytokine.
conclusion: These findings demonstrate that IFN-γ or IL-4 can regulate the expression 
of histone acetyl transferases and histone methyl transferases independently of effects 
on proliferation and that upregulation of the histone demethylase, KDM6B, assists phe-
notypic polarization by both cytokines.
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inTrODUcTiOn
Macrophages are important, multifunctional cells in the innate 
immune system. Their ability adopt a spectrum of phenotypes 
that perform greatly different functions in response to diverse 
activators has become increasingly recognized (1). IFN-γ is an 
important pro-inflammatory cytokine in responses to certain 
pathogens, promoting toll-like receptor expression and inducing 
greater production of nitric oxide, pro-inflammatory cytokines, 
such as TNFα (2, 3) and extracellular proteases, including some 
metalloproteinases (4), which together promote invasion of 
macrophages to sites of inflammation and enhance microbial 
killing. IFN-γ is also an established link between the innate 
and acquired immune systems, especially in the context of 
autoimmunity, where it not only promotes activation of Thelper1 
lymphocytes but also increases major histocompatibility complex 
(MHCII) expression leading to enhanced antigen presentation by 
macrophages (3). Macrophages activated by IFN-γ are believed 
to provoke tissue injury, for example joint destruction during 
rheumatoid arthritis and atherosclerotic plaque rupture leading 
to myocardial infarctions (5). On the other hand, IL-4 or IL-13 
provoke a macrophage phenotype that has greater scavenger 
receptor activity and increased release of anti-inflammatory and 
fibrogenic factors (6, 7), suggesting a primary role in clearance of 
cell debris and promotion of tissue repair. Although apparently 
more benign, these macrophages may help tumor cells evade 
immune surveillance and can provoke allergy or lung hyper-
sensitivity (6, 7). Greater understanding of the mechanisms that 
underlie generation of these diverse macrophage phenotypes is, 
therefore, warranted in order to design strategies to avoid these 
unwanted complications.
Responses to IFN-γ are mediated through signal transducer 
and activator of transcription-1 and several so-called interferon 
response factors (IRFs) (8–10), especially IRF-7 and IRF-9 (1), 
whereas IL-4 and IL-13 activate STAT-6 (11) and IRF-4 (1). 
Consequently, IFN-γ and IL-4 provoke widely different transcrip-
tional responses, effectively defining their divergent phenotypes 
(12). Moreover, the ability of IFN-γ to downregulate many 
IL-4-induced genes [for example cluster E vs F of reference (12) 
and module 15 of reference (1)] amplifies these phenotypic dif-
ferences. Participation of epigenetic mechanisms in macrophage 
polarization has also been demonstrated (13). In particular, the 
ability of IFN-γ or IL-4 to alter the local histone code, which 
determines whether the relevant transcription factors have access 
to promoter sequences, has been implicated in their ability to 
drive cells toward different phenotypes (14–17). However, knowl-
edge regarding the role of specific histone-modifying enzymes 
is presently fragmentary and sometimes conflicting (13). We, 
therefore, took an unbiased approach by using an RT-qPCR array 
of 84 epigenetic regulators to investigate the impact of IFN-γ and 
IL-4, singly and in combination (to look for antagonistic effects) 
on human primary macrophages. We identified 11 genes up- or 
downregulated by the cytokines but some of these were affected, 
at least in part, secondary to inhibition of cell proliferation. 
Lysine demethylase 6B (KDM6B) was the only putative activator 
of transcription that was upregulated by both IFN-γ and IL-4, 
thereby implying a functional role in promoting gene expression 
by both cytokines. To investigate this hypothesis directly, the 
functional consequences of inhibiting and silencing KDM6B 
were investigated further.
MaTerials anD MeThODs
cell Preparation
Monocytes were isolated from the EDTA anticoagulated blood 
of healthy volunteers. Written informed consent was given 
under National Research Ethics Service approval from Frenchay 
Research Ethics Committee reference 09/H0107/22 and South 
West 4 Research Ethics Committee reference 10/HO102/72, 
respectively. Mononuclear cells were isolated using Ficoll-Paque 
Plus (GE Healthcare Life Sciences), red blood cells were lysed 
with 150  mM ammonium chloride/0.1% BSA, and monocytes 
were allowed to adhere to plastic in RPMI 1640/1% human serum 
AB (SigmaAldrich) for 1  h. Non-adherent cells were removed 
with warm Dulbecco’s phosphate buffered saline (D-PBS; Gibco), 
and the medium was replaced with RPMI 1640/10% fetal bovine 
serum (FBS; SigmaAldrich) for 1 h. Based on staining with Rabbit 
anti-(human CD14) antibody, Ab78313, adhered cells were at 
least 85% monocytes. Monocytes were differentiated into mac-
rophages in RPMI 1640 medium containing 10% FBS and 20 ng/
mL of colony-stimulating factor-1 (human recombinant CSF-1, 
R & D systems), which was replenished on day 3. Approximately 
80% of the resulting cells were macrophages based on positive 
staining with mouse monoclonal anti-CD68 (M0876, Dako). 
Differentiated macrophages were treated for 6, 18, 32 and 48 h in 
the same medium with either 100 ng/mL of recombinant human 
interferon-γ (IFN-γ) (R & D systems) or 10 ng/mL of recombi-
nant human interleukin-4 (IL-4) (R & D systems). AZD1152 was 
purchased from Selleck.
rna isolation, reverse Transcription,  
and Transcript Quantification
Total RNA was isolated from the macrophages prepared from 
three different healthy donors using the PureLink™ RNA Mini 
Kit (Ambion). Total RNA was quantified using an ND1000 NaNo 
Drop spectrophotometer, and 100 ng were reversed transcribed 
using the QuantiTect Reverse Transcription Kit (Qiagen) with 
additional genomic DNA elimination step indicated in the 
manufacturer’s instructions. For quantitative polymerase chain 
reaction (qPCR), the cDNA samples were diluted 1:3 in 10 mM 
Tris–HCl, pH 8.0 and amplified using the LightCycler 480 
SYBR Green I Master mix (Roche) in an Eco Real-Time PCR 
System (Illumina), using primer sets shown in Table  1. Data 
were normalized to total RNA in each reaction. For qPCR array, 
RNA from three different donors was analyzed using the Human 
Epigenetic Chromatin Modification Enzymes RT2 Profiler PCR 
Array (Qiagen) according to the manufacturer’s protocol. Briefly, 
total RNA (400  ng, genomic DNA eliminated) was reverse 
transcribed using RT2 First Strand Kit (Qiagen) and diluted in 
RNase-free water. The amplification reaction was conducted in 
384 well format in a Roche LightCycler 480 (95°C 10  min for 
one cycle followed by 95°C 15 s and 60°C 1 min for 45 cycles). 
Threshold cycle (CT) values were exported and analyzed using 
TaBle 1 | Primers used for rT-qPcr.
gene sequences for Pcr from 5′ to 3′
AURKB Forward AGTGCCTTGGACCCCAGCTCTC
Reverse GTGACAGGCTCTTTCCGGAGGACT
CCL7 Forward CCAACATGAAAGCCTCTGCAGCAC
Reverse TCTGTAGCTCTCCAGCCTCTGCTT
CD206 Forward CGGTGACCTCACAAGTATCCACAC
Reverse TTCATCACCACACAATCCTCCTGT
CIITA Forward GGAGGCTTATGCCAATATCGCGGA
Reverse CCCAACTTCTGCTGGCATCTCCAT
CYCLIN E Forward CGCAGGGAGCGGGATGCGAA
Reverse CCGTCCTGTCGATTTTGGCCATTTC
ESCO2 Forward TGCAGAACCCATCAAACAGGCATT
Reverse ATTGCCAAGCCCTAGGACATTCCG
KAT2A Forward CTCGGCTTGCAAGGCCAATGAAAC
Reverse CTCCAAGTGGGATACGTGGTCAGC
KDM6A Forward CCATGAACACAGCACAGCAGGCAT
Reverse CTTGGCAGGACTGGACAGGTCATC
KDM6B Forward GCAACCACCGCCTGCGTGCCTTAC
Reverse CGGGAATGCCTGGGTTCGGCTCCA
NCOA1 Forward TGGGTTGCCTCTTCATTTACAGGG
Reverse TGGCTTCAGGGATGCTTTATTATCCT
SOCS3 Forward CCCCCAGAAGAGCCTATTACATCT
Reverse GTACTGGTCCAGGAACTCCCGAAT
PALLD Forward GTATAAAGCCCGATACCTGCCCCG
Reverse CTGGAGTTGCTGGAGCTTCAGAGG
PCNA Forward CATGGGCGTGAACCTCACCAGTATG
Reverse ATACTAGCGCCAAGGTATCCGCGT
PRMT7 Forward TTCCAGTTCTGCTTTAGGACCCGC
Reverse CCTCCGCTGCTACCACTTTTACCG
SETD6 Forward CGAGGAAACGCGCTCTTAGACCA
Reverse CTCGCTCACCTTGGGACTCAGCTC
SMYD3 Forward GATGGAGCCGCTGAAGGTGGAAAA
Reverse CCAAGGGATCCGAGCGGAAGAGTA
SUV39H1 Forward ATAGACAACCTTGACGAGCGGCTG
Reverse ACGGGGTCCACTTGCATGTTGTAA
VAMP5 Forward GGTGGTTGGTGTCCTGCTCATCAT
Reverse CTTCAGGACCAGCTGGGTCAGTTC
WHSC1 Forward GATGCGACGCACCGCAGTGTTCTA
Reverse CCGAGGATTTCTGGTGCCTGCTT
36B4 Forward GCCAGCGAAGCCACGCTGCTGAAC
Reverse CGAACACCTGCTGGATGACCAGCCC
3
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web based SABiosciences PCR Array Data Analysis Software.1 A 
panel of five housekeeping genes integral to the array were used 
to calculate for each probe ΔCT =  (CT probe −  CT average of 
housekeeping genes). The values of ΔΔCT = ΔCT experimental 
sample − ΔCT control were calculated for each probe and con-
verted to fold changes = (2(−ΔΔCT)). For transcriptomic analysis, 
purified RNA samples from four different donors were submitted 
to the Illumina Gene Expression ServiceXS (Leiden, Netherlands) 
and were processed for analysis on the Illumina HumanHT-12 
1 http://pcrdataanalysis.sabiosciences.com/pcr/arrayanalysis.php.
v4 microarray as described in detail.2 The results were deposited 
under number GSE83957. Fold changes and statistics (multiple 
testing corrections) of generated raw data were performed using 
GeneSpring (Agilent Technologies). Venn Diagrams were gener-
ated by using web-based software.3 Gene ontology enrichment 
(GOE) and KEGG pathway analysis were performed using the 
DAVID public database.4
Western Blotting
Macrophages were lysed in SDS lysis buffer [2% SDS (w/v)/16% 
glycerol (v/v) in 50  mM Tris, pH 6.8]. Protein was measured 
(Micro BCA kit, Thermo Scientific Pierce). Equal amounts 
of reduced protein were fractionated by SDS-polyacrylamide 
gel electrophoresis, transferred to PVDF membranes (Merck 
Millipore), blocked in TBST/5% skimmed milk followed by incu-
bation in primary antibody. Proteins were detected using appro-
priate HRP-conjugated secondary antibodies (SigmaAldrich) and 
enhanced chemiluminescence (Immobilon, Merck Millipore) 
and Hyperfilm™ ECL (GE Healthcare Life Sciences). The anti-
bodies used were Phospho-Rb-Ser807/811, E2F1, KDM6A, and 
SMYD3 (Cell Signaling), Histone H3 and Histone H3-Phospho 
S10 (Abcam), GAPDH (Millipore), and p27kip1 (BD Biosciences).
Macrophage Proliferation
To measure S-phase entry to the cell cycle, macrophages were 
labeled with 10 µM BrdU (SigmaAldrich) for 24 h. Cell prolif-
eration was quantitated by immunohistochemistry as previously 
described (18). The percentage of BrdU positive nuclei was 
counted using NIH ImageJ software.
recombinant adenoviruses and infection 
of Macrophages
Recombinant adenovirus encoding for human p27kip1 was a kind 
gift from Professor Betsy Nabel (NIH, MD, USA). This virus and 
a control adenovirus expressing destabilized, enhanced green 
fluorescent protein (dsEGFP) were used as described previously 
(19). To generate the adenovirus expressing E2F1, the plasmid 
E2F1 wt-pGex2TK containing the coding sequence for human 
E2F1 from William Kaelin (20), was purchased from Addgene 
(Addgene plasmid # 21668). It was amplified using KOD DNA 
polymerase (Merck-Millipore, UK) to include EcoRI and BamH1 
flanking sites and subcloned into the shuttle vector pDC515io 
from Microbix (ON, Canada). Recombination (Flp/FRT medi-
ated) was performed in 293IQ cells to inhibit transgene protein 
expression (a gift from Dr. D. Matthews, University of Bristol) 
(21). For gene silencing, short hair pin (Sh) sequences were 
predicted using http://cancan.cshl.edu/RNAi_central/RNAi.
cgi?type=shRNA. The sequences used to silence KDM6A, 
5′CTGCCATTAAATGCTACTTAAATAGTGAAGCCACAGA 
TGTATTTAAGTAGCATTTAATGGCAT3′, KDM6B, 5′CGCCC 
AGTCTGTGAAACCGAAGTAGTGAAGCCACAGATGTA 
2 http://www.embl-ebi.ac.uk/arrayexpress/experiments/E-GEOD-48977/
protocols/.
3 http://genevenn.sourceforge.net/.
4 https://david.ncifcrf.gov/.
FigUre 1 | Time course analysis of sOc3 and cD206 mrna in response to interferon-γ or interleukin-4 (il-4). Time course analyses of mRNA levels 
(RT-qPCR) of SOC3 and CD206 mRNA in response to by IFN-γ or IL-4 treatment of 4-day differentiated human monocyte-derived macrophages. (a) SOC3 and (B) 
CD206. Results are expressed as mRNA relative to time 0 untreated control. IFN-γ (solid line) and IL-4 (dashed line). Data are the mean ± SEM, n = 3 blood donors. 
p Values were calculated using ANOVA with Dunnett post-test. *indicates p < 0.05, **indicates p < 0.01 compared with control.
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CTTCGGTTTCACAGACTGGGCA3′ and firefly luciferase, 
5′CGCCTGAAGTCTCTGATTAATAGTGAAGCCACAGAT 
GTATTAATCAGAGACTTCAGGCGGT3′, as a control, were 
embedded in the backbone of the primary microRNA-30, as 
described previously (22) and were synthesized by Eurofins. 
DNA sequences for modified microRNA-30 were synthesized by 
Eurofins, cloned into the Nhe1-BamH1 sites of the shuttle vector 
pDC515 and adenoviruses were generated as described above. 
Virus stocks were purified by CsCl banding and titrated by plaque 
assay. Monocytes differentiated for 4  days were infected with 
Ad-p27kip1 or Rad66 at 108 plaque forming units (pfu)/ml for 24 h. 
Alternatively, cells were infected with Ad-E2F1 or Ad-dsEGFP at 
5 × 107 pfu/mL for 20 h followed by further 18 h treatment in the 
presence of IFN-γ or IL-4. For gene silencing, cells were infected 
with shKDM6A, shKDM6B, or shLuciferase (shLUC) viruses at 
2 ×  108 pfu/ml for 72 h before stimulation with IFN-γ or IL-4 
for 6 h.
statistical analysis
Normality of data sets was analyzed by the method of Kolmogorov 
and Smironov. Differences between means of normally dis-
tributed variables with similar variances were analyzed using 
a paired Student’s t-test or, for multiple comparisons, ANOVA 
followed by a Dunnett or Student–Newman–Keuls post-test, as 
appropriate. For the array, data from the Benjamini–Hochberg 
method were used for multiple testing correction. All data are 
from independent experiments on cells from different donors 
and are presented as mean ± SE. *indicates p < 0.05, **indicates 
p < 0.01, ***indicates p < 0.001.
resUlTs
effects of iFn-γ and il-4 on mrna levels 
of epigenetic regulatory genes
To identify optimal time points for transcriptomic analysis, 
we measured changes in the mRNA expression of phenotypic 
markers SOCS3 (23) and CD206 (12). As expected, IFN-γ 
but not IL-4 induced SOCS3 mRNA expression (Figure  1A), 
which was significant by 6 h and remained maximal at 18 and 
32  h: it then declined but was still significantly elevated above 
untreated controls at 48 h (Figure 1A). Also as expected, IL-4 
stimulated but IFN-γ inhibited CD206 mRNA expression after 
48  h (Figure  1B). Interestingly, however, IFN-γ and IL-4 both 
induced CD206 to a similar extent at 6 h but the effect of IL-4 
increased further from 18-48  h, whereas that of IFN-γ waned 
such that CD206 expression had declined below control levels 
after 32 and 48 h (Figure 1B). We, therefore, chose the 18 h and 
48 h samples from these experiments to capture the differential 
effects of IFN-γ and IL-4 on steady-state mRNA levels of 84 epi-
genetic regulators using a commercially available RT-qPCR array. 
The combination of IFN-γ and IL-4 was also investigated because 
antagonistic interactions might enhance phenotypic differences 
(see Introduction). The results were normalized against a panel 
of five housekeeping genes integral to the profiler and significant 
changes were identified by using the array manufacturer’s soft-
ware, which yielded values of mean fold change and p values after 
false discovery rate correction (Table 2). Eight significant differ-
ences and three non-significant trends that were subsequently 
found significant by conventional RT-qPCR are highlighted in 
bold. There were more significant responses to IFN-γ (10 gene 
changes at 18 h, of which 7 persisted at 48 h) than IL-4 (7 gene 
changes, only 2 of which were significant at both 18 h and 48 h). 
Contrary to our expectation of antagonistic responses, IFN-γ 
and IL-4 appeared to produce additive effects on the expression 
of epigenetic regulators (Table 2). The significant changes from 
the RT-qPCR screen were validated and extended by a detailed 
time course study using the full set of samples (Figures 2A–C 
and 3A–H). All the significant changes observed in the array were 
confirmed; and also the trends toward increase of KDM6B by 
IL-4 and decrease of KAT2A and SETD6 by IFN-γ were shown 
to be significant by standard RT-qPCR normalized against total 
RNA, which meets current recommendations (24). Only three 
genes, namely CIITA, KDM6B, and NCOA1 showed increased 
expression (Figures  2A–C), whereas the other 8, namely 
AURKB, ESCO2, KAT2A, PRMT7, SETD6, SMYD3, SUV39H1, 
TaBle 2 | iFn-γ- or interleukin-4 (il-4)-induced changes in expression of histone-modifying enzymes.
iFn-γ il-4 iFn-γ + il-4
Fold change Fold change Fold change
Function gene 18 h 48 h 18 h 48 h 18 h 48 h
Kinase AURKB −20.84* −70.52* −10.48* −4.05* −27.56* −86.02*
Acetyltransferase CIITA 11.06** 2.59* 11.32*
ESCO2 −56.95** −160.89** −15.88** −4.59** −62.6** −83.09**
KAT2A −2.51* −2.3295^ −2.3* −3.64*
NCOA1 2.48*** 2.94** 2.58** 2.16**
Demethylase KDM6B 2.83** 3.05 NS 2.31# 3.63** 2.9*
Methyltransferase PRMT7 −2.23** −2.39**  −2.26* −3.36**
SETD6 −4.0798 −2.54 NS −2.89* −4.94* −5.16*
SMYD3 −2.52* −2.54* −3.41* −4.94**
SUV39H1 −5.65** −3.45* −3.49** −2.07 NS −6.11** −5.16*
WHSC1 −2.54* −2.46* −2.03* −3.7* −2.41*
Four-day differentiated human monocyte-derived macrophages were treated with 100 ng/mL IFN-γ or 10 ng/mL IL-4 singly or in combination for 18 h or 48 h. Extracted RNA 
samples were subjected to analysis by the Human Epigenetic Chromatin Modification Enzymes RT2 Profiler PCR Array (QIAGEN). p Values were calculated based on full plate 
normalization with twofold change as a cut off value (hence the blank values) and using a Student’s t-test of the replicate 2(-Delta Ct) values for each gene in the control group and 
treatment groups.
*indicates p < 0.05, **indicates p < 0.01, ***indicates p < 0.001, #p = 0.0502, ^p = 0.055, p = 0.054, NS indicates non-significant fold changes, n = 3 donors.
AURKB, aurora kinase B; CIITA, class II major histocompatibility complex transactivator; ESCO2, Establishment of Sister Chromatid Cohesion N-Acetyltransferase 2; KAT2A, lysine 
acetyltransferase 2A, PCAF-B; NCOA1, nuclear receptor coactivator 1, Steroid Receptor Coactivator-1 (SRC-1); KDM6B, Lysine Demethylase 6B, JMJD3; PRMT7, Protein Arginine 
Methyltransferase 7; SETD6, SET Domain Containing 6; SMYD3, SET And MYND Domain Containing 3; SUV39H1, Suppressor Of Variegation 3-9 Homolog 1; WHSC1, Wolf-
Hirschhorn Syndrome Candidate 1.
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and WHSC1 showed decreased expression (Figures  3A–H). 
The IFN-γ-induced increases in CIITA, KDM6B, and NCOA1 
showed a similar pattern to SOCS3, with significant induction by 
6 h and a tendency to decline thereafter (Figures 1A and 2A–C). 
The IL-4-induced increase in KDM6B was also significant by 6 h 
of treatment but then declined, unlike CD206, which remained 
elevated (Figures  1B and 2B). The decreased expression of 
AURKB, ESCO2, KAT2A, PRMT7, SETD6, SMYD3, SUV39H1, 
and WHSC1 was delayed to 18 h and beyond (Figures 3A–H). 
In the few cases, where it was possible, we sought to confirm 
the mRNA data by protein or activity measurements. In the 
case of SMYD3, IFN-γ significantly reduced protein levels after 
48 h (Figure 4A). Either IFN-γ or IL-4 inhibited AURKB activ-
ity measured by the phosphorylation of histone3 on serine-10 
(H3pS-10) (Figure  4B) (25). Consistent with this, we demon-
strated that AZD1152, a pharmacological inhibitor of AURKB 
(26) also inhibited H3pS-10 to the same extent as either IFN-γ 
or IL-4 (Figure 4C).
Decline in histone-Modifying enzyme 
expression Was concurrent with 
Decreased Proliferation
Interestingly, phosphorylation of H3pS-10 by AURKB is neces-
sary for chromatin reorganization during mitosis (27–29), 
ESCO2 promotes sister chromatid cohesion (30), SUV39H1 
also has a role in chromosome segregation (31, 32) and WHSC1 
has been ascribed a role in DNA repair during replication (33). 
Hence all these enzymes have established roles in cell division. 
Consistent with other previous literature (34, 35), we found 
that IFN-γ or IL-4 inhibited phosphorylation of retinoblastoma 
protein (Rb, Figure  4B), confirming that they arrested cells at 
the G1/S checkpoint in the cell cycle (36). Treatment with either 
IFN-γ or IL-4 also profoundly decreased BrdU incorporation as 
a marker of DNA replication in our macrophages (Figure 4D). 
These observations led us to question whether decreased expres-
sion of histone-modifying genes by IFN-γ or IL-4 might be the 
incidental consequence of inhibiting proliferation.
growth Factor Depletion causes  
a Decline in Proliferation and  
aUrKB and escO2 expression
To investigate the relationship between proliferation and mRNA 
levels of epigenetic regulators further, we cultured macrophages 
differentiated for 6  days for four more days either with or 
without growth factors, which arrests cells in the early G1 
phase of the cell cycle. Consistent with this, prolonged culture 
decreased phosphorylated retinoblastoma protein (pRb) and 
H3pS-10 levels and these effects were even greater without 
growth factors (Figure 5A). Furthermore, BrdU incorporation 
after 10 days of differentiation declined by a further 76% (n = 4, 
p = 0.002) when growth factors were omitted. Similarly, expres-
sion of AURKB and ESCO2 mRNA each declined significantly 
between 6 and 10 days of culture and the decrease was greater 
after growth factor depletion (Figures  5B,C), suggesting that 
their expression was at least partly dependent on proliferation. 
Growth factor depletion did not affect IFN-γ or IL-4 upregulated 
genes, CIITA, KDM6B, or NCOA1, or the downregulated genes 
KAT2A, PRMT7, SETD6, or SMYD3 (Figure  5D). SUV39H1 
and WHSC1 expression showed non-significant trends toward 
reduction (Figure 5D).
FigUre 2 | Validation of upregulated genes. Time course analyses of 
mRNA levels (RT-qPCR) of genes upregulated by IFN-γ or interleukin-4 (IL-4) 
treatment of 4-day differentiated human monocyte-derived macrophages. (a) 
CIITA, (B) KDM6B, and (c) NCOA1. Results are expressed as mRNA relative 
to time 0 untreated control. IFN-γ (solid line) and IL-4 (dashed line). Data are 
the mean ± SEM, n = 3 blood donors. p Values were calculated using 
ANOVA with Dunnett post-test. *indicates p < 0.05, **indicates p < 0.01 
compared with control.
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inhibition of Proliferation by 
Overexpressing p27kip1 causes a Profound 
Decline in aUrKB, escO2, sUV39h1, and 
Whsc1 expression
IFN-γ or IL-4 arrest cell proliferation at the G1/S checkpoint 
thanks to elevation of the cyclin-dependent kinase inhibitor 
p21Cip1 (34, 35). We sought to inhibit proliferation at the G1/S 
checkpoint by an alternative mechanism. Given that gene silenc-
ing is inefficient in macrophages, we overexpressed the cyclin-
dependent kinase inhibitor p27kip1 (37) from an adenovirus. 
Infection with the p27kip1 expressing virus increased p27kip1 
protein, as expected (Figure  6A), and dramatically decreased 
BrdU incorporation (Figure 6B), pRb (Figure 6C) and H3pS-10 
(Figure 6D). Hyperphosphorylation of Rb releases the S-phase 
transcription factor, E2F, which induced multiple genes that 
include Cyclin E and proliferating cell nuclear antigen (PCNA) 
(38). As expected, therefore, overexpression of p27kip1 profoundly 
decreased mRNA levels of cyclin E (84 ± 2%) and PCNA (86 ± 6%, 
both n = 3, p < 0.01), confirming G1/S blockade. Overexpression 
of p27kip1 decreased mRNA levels of AURKB, ESCO2, SUV39H1, 
and WHSC1 (Figure 6E), to a similar extent as IFN-γ or IL-4. 
By contrast, levels of the other genes downregulated by IFN-γ, 
namely KAT2A, PRMT7, SETD6, and SMYD3 were not signifi-
cantly reduced by p27kip1 overexpression (Figure 6E) and were, 
therefore, clearly independent of inhibition of proliferation by 
either growth factor depletion or p27kip1 overexpression. Steady-
state mRNA levels of the genes upregulated by IFN-γ or IL-4, 
namely CIITA, KDM6B, and NCOA1, were not decreased or even 
increased by overexpression of p27 kip1 (Figure 6E).
Overexpression of e2F1 rescued the 
Downregulation of aUrKB, escO2, 
sUV39h1, and Whsc1
It has been suggested that AURKB is a direct target of transcrip-
tion factor E2F (29). Furthermore, when we interrogated the 
ENCODE database, we found chromatin immunoprecipitation 
evidence for binding of E2F transcription factors to the proximal 
promoters of the AURKB, ESCO2, SUV39H1, and WHSC1 
genes, whereas CIITA, KDM6B, and NCOA1 had no such sites. 
We, therefore, investigated whether the effects of IFN-γ or IL-4 
on AURKB, ESCO2, SUV39H1, and WHSC1 could be reversed 
by adenovirus-mediated overexpression of E2F1. Infection with 
the E2F1 expressing virus increased E2F1 protein (Figure  7A) 
and, as expected, the mRNA levels of the known E2F responsive 
genes, Cyclin E and PCNA (38) (Figures  7B,C). E2F1 gene 
transfer completely reversed the inhibitory effect of IFN-γ and 
IL-4 on AURKB, ESCO2, SUV39H1, and WHSC1 mRNA levels 
(Figures 7D–G), except in the case of AURKB for which the effect 
of IL-4 was only partly reversed (Figure 7D). These data provided 
further support for the conclusion that the effects of IFN-γ or IL-4 
on these genes were, at least partly, mediated indirectly through 
inhibition of proliferation.
impact of Pharmacological inhibition 
and or shrna silencing of KDM6B on 
Macrophage Polarization
From the above results we concluded that increased expression 
of CIITA, KDM6B, and NCOA1 and decreased expression of 
KAT2A, PRMT7, SETD6, and SMYD3 was independent of any 
effects on proliferation. To begin to understand the impact of these 
changes on macrophage phenotype, we chose to further investi-
gate KDM6B, which was the only transcriptional enhancer that 
was increased at the mRNA level by both IFN-γ and IL-4. Given 
that the action of KDM6B is demethylation of lysine 27 on his-
tone3, which is associated with increased gene transcription (13), 
this upregulation might be expected to promote transcriptional 
FigUre 3 | Validation of downregulated genes. Time course analyses of mRNA levels (RT-qPCR) of genes downregulated by IFN-γ and/or interleukin-4 (IL-4) 
treatment of 4-day differentiated human monocyte-derived macrophages. (a) AURKB, (B) ESCO2, (c) KAT2A, (D) PRMT7, (e) SETD6, (F) SMYD3, (g) SUV39H1, 
and (h) WHSC1. Results are expressed as mRNA relative to time 0 untreated control. IFN-γ (solid line) and IL-4 (dashed line). Data are the mean ± SEM, n = 3 
blood donors. p Values were calculated using ANOVA with Dunnett post-test. *indicates p < 0.05, **indicates p < 0.01 compared with control.
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FigUre 4 | effect of iFn-γ, interleukin-4 (il-4) or aZD1152 on sMYD3 protein and aUrKB activity. Four-day differentiated human blood monocyte-derived 
macrophages were treated with IFN-γ or IL-4 for 24 h or as indicated. Extracts were prepared for Western blotting of (a) SMYD3, (B) Histone H3-S10 
phosphorylation (H3pS-10), and phosphorylated retinoblastoma protein and the densitometry results were expressed relative to untreated control. (c) H3pS-10 after 
treatment with 100 nM AZD1152, a pharmacological inhibitor of AURKB, or vehicle (DMSO) for 8 h. (D) 10 µM BrdU was added for a further 24 h and the 
percentage of nuclear BrdU positive cells was determined by immunocytochemistry and counting. Data are the mean ± SEM, n = 3 blood donors. p Values were 
calculated using a paired or a single value t-test as appropriate. *indicates p < 0.05, **indicates p < 0.01, ***indicates p < 0.001 compared with 24 h control.
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responses to both cytokines. Conversely, inhibition and silencing 
of KDM6B might decrease gene expression associated with IFN-γ 
and IL-4. To narrow down the search for those genes regulated 
by KDM6B, either on its own or in combination with KDM6A, 
we first performed a microarray study of transcripts upregulated 
by IFN-γ or IL-4 in the presence and absence of the combined 
KDM6A and B inhibitor GSK-J4 (39). From preliminary time 
course and dose-response studies (results not shown), 6  h 
exposure was sufficient and 60 µM GSK-J4 was chosen because it 
significantly suppressed TNFα induction by lipopolysaccharide 
(LPS) by approximately 70% [confirming previous results (39)]. 
CD206 induction by IL-4 was also inhibited, albeit by only 30% 
(both p <  0.05), whereas a housekeeping gene, 36B4, was not 
affected. From these pre-validated samples, the transcriptomic 
analysis showed that IFN-γ significantly upregulated 906 and 
IL-4 upregulated 271 transcripts after 6 h (a complete gene list is 
deposited under GSE83957). Only 62 of these (6%) were upregu-
lated by both IFN-γ and IL-4, which confirms the differential 
phenotypes stimulated by these two cytokines, as demonstrated 
more extensively previously (1). This data also emphasizes how 
unusual KDM6B is in being upregulated by both IFN-γ and 
IL-4. Of the 831 IFN-γ upregulated transcripts recognized by 
the genevenn program used to generate Venn diagrams, 181 
(22%) were significantly decreased by the additional presence of 
GSK-J4 (Figure 8A). Using GOE and KEGG pathway analysis, 
these genes were associated with several aspects of immune cell 
FigUre 5 | effect of growth factor depletion on the proliferation of 
macrophages, aUrKB activity and mrna levels of aUrKB, escO2, 
sUV39h1, and Whsc1. Human blood monocytes were differentiated in 
10% FBS and CSF-1 for 6 days. On day 6, cells were either extracted for 
Western blotting and mRNA isolation or kept in culture until day 10 in either 
serum-free RPMI 1640 or serum and CSF-1 supplemented media before 
extraction. (a) Levels of phosphorylated retinoblastoma protein and AURKB 
activity (H3pS-10) were measured by Western blotting. Levels of mRNA 
relative to day 6 differentiated macrophages were determined by RT-qPCR 
for (B) AURKB, (c) ESCO2, (D) other genes as indicated. Data are the 
mean ± SEM, n = 3 blood donors. p Values were calculated using an ANOVA 
with Student–Newman–Keuls post-test. *indicates p < 0.05, **indicates 
p < 0.01, ***indicates p < 0.001.
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function and transcriptional activation (Tables 3 and 4). Of the 
254 IL-4 upregulated transcripts only 28 (11%) were significantly 
reduced by the additional presence of GSK-J4 (Figure  8B). 
There were insufficient genes in this cluster to perform GOE or 
KEGG pathway analysis. Only two transcripts (C17orf87 and 
LOC650919), neither associated with a known function, were 
common to both lists. The genes most inhibited by GSK-J4 in the 
presence of either IFN-γ or IL-4 are illustrated by heat maps in 
Figures 8C,D, respectively, with the details of these and further 
genes listed in Table  5. Heading the list of IFN-γ upregulated, 
GSK-J4 downregulated genes were CCL7 and CCL8, which are 
known genes associated with activation by IFN-γ (40). Heading the 
list of IL-4 upregulated, GSK-J4 downregulated gene was CD209, 
which is an established IL-4 responsive gene (41). A selection of 
the more abundant transcripts that were inhibited at least twofold 
by GSK-J4, were chosen for further analysis. Because there were 
so few abundant IL-4 stimulated, GSK-J4 inhibited transcripts 
in the array, we also included CD206, which was used for initial 
sample validation but just failed to reach significance in the array 
experiment (i.e., a false negative). First, upregulation by IFN-γ 
or IL-4 and its reversal by GSK-J4 was confirmed by RT-qPCR 
(Figures 8E,F, respectively). GSK-J4 is non-selective for KDM6A 
and KDM6B (39). Hence, to distinguish the roles of KDM6A and 
KDM6B, the effects of silencing one, the other or both was investi-
gated by using shRNA. Given that silencing is difficult in primary 
macrophages, we used adenovirus-mediated delivery of shRNAs 
selective for KDM6A or KDM6B and compared these to delivery 
of a control adenovirus that expressed shRNA against firefly lucif-
erase (shLUC). The housekeeping gene, 36B4, was also studied as 
a further control. Based on mRNA levels, silencing of KDM6A 
and B was highly selective, albeit incomplete at the maximum 
tolerable adenovirus dose (Figure  9A). Specificity and efficacy 
was confirmed at the protein level for KDM6A (Figure 9B) but no 
suitable antibody is available for KDM6B. The effects of KDM6A 
and B silencing were measured in the presence of IFN-γ or IL-4. 
From these results, the induction of CCL7 by IFN-γ depended 
selectively on KDM6A, whereas that of VAMP5 required KDM6A 
and B redundantly (Figure 9C). The induction of CD206 by IL-4 
also required KDM6A and B redundantly, whereas that of PALLD 
depended selectively on KDM6B (Figure 9C). We concluded that 
a subgroup of transcripts upregulated by IFN-γ or IL-4 depended 
on KDM6B, either on its own or redundantly with KDM6A.
DiscUssiOn
Main Findings
Using a focused array, we demonstrated that IFN-γ or IL-4 modu-
late the mRNA expression of at least seven epigenetic regulators 
in human blood monocyte-derived macrophages, independently 
of any effects on cell proliferation. CIITA, KDM6B, and NCOA1 
showed increased mRNA expression within 6  h of stimula-
tion, whereas KAT2A, PRMT7, SETD6, and SMYD3 showed 
decreased expression that required at least 18 h of treatment. The 
effects were confirmed at the level of protein for SMYD3. Based 
on similar effects of growth factor depletion or overexpression 
of p27kip1, we concluded that IFN-γ or IL-4 decreased expression 
of AURKB, ESCO2, SUV39H1 and WHSC1 mRNA and AUKB 
activity, at least partly, as a consequence of cell cycle arrest at the 
G1/S checkpoint. Furthermore, this decreased expression could 
be reversed by overexpression of E2F1, which is known from 
published chromatin immunoprecipitation (ENCODE) studies 
to bind directly to the relevant promoter regions. These data 
expand the list of epigenetic regulators the expression of which 
is regulated by IFN-γ and IL-4. As a first step to establishing 
whether these changes impact on macrophage phenotype, we 
demonstrated by pharmacological inhibition and shRNA silenc-
ing that KDM6B participates in a subset of the divergent gene 
expression changes in response to IFN-γ and IL-4.
role of Diverse epigenetic regulators
In general, several families of enzymes that can alter the phospho-
rylation, acetylation, and methylation status of specific histone 
FigUre 6 | effect of overexpression of the cyclin-dependent kinase inhibitor p27Kip1. Human blood monocytes differentiated for 4 days were infected with a 
recombinant adenovirus overexpressing p27kip1 (Ad:p27) or control, destabilized, enhanced green fluorescent protein at 1 × 108 plaque forming units/ml for 24 h. (a) 
p27kip1 protein overexpression by Western blotting. (B) BrdU was added 24 h after adenovirus infection in fresh medium for further 24 h and proliferation measured 
as percentage BrdU positive cells using immunocytochemistry. (c) A representative Western blot and relative levels of phosphorylated retinoblastoma protein. (D) A 
representative Western blot and relative levels H3pS-10. p Values were calculated using paired or single value t test. *indicates p < 0.05, **indicates p < 0.01 and 
***indicates p < 0.001 compared with Ad:control. (e) Effect of p27 overexpression on the mRNA levels of genes regulated by IFN-γ and interleukin-4. p Values 
calculated using an ANOVA with Dunnett post-test, **indicates p < 0.01 compared with Ad:control. Data are presented as the mean ± SEM, n = 3 blood donors.
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residues play a major role in epigenetic regulation (42–44). 
Histone H3S-10 phosphorylation catalyzed by AURKB has been 
implicated in chromatin condensation during mitosis (45, 46). 
Moreover, the finding that AURKB is an E2F target (29) led to the 
conclusion that it is a useful marker of cell proliferation, similar to 
PCNA. Our data showing that AURKB is downregulated by IFN-
γ and IL-4-induced cell cycle arrest and is restored by the E2F1 
extend these conclusions to primary macrophages. Previous work 
showing that the AURKB inhibitor, AZD1152, abrogates growth 
of human acute myeloid leukemia cells (47) and that growth 
arrest of mouse Raw264.7 macrophages by H. Pylori is associated 
with downregulation of AURKB (48) are also consistent with our 
conclusions.
Histone acetyl transferases (HATs) promote opening of the 
chromatin and enhance transcription, whereas histone de-acet-
ylases (HDACs) have the opposite effect (49–51). The ability of 
CIITA to recruit HATs, including KAT2A (also known as pCAF-
B) and NCOA1 (also known as SRC-1), to the promoter of the 
major histocompatibility complex-II (MHC-II) gene, has been 
extensively studied in macrophages (52, 53). Given the previous 
literature, CIITA upregulation by IFN-γ could be seen as a posi-
tive control for our array study. However, we also found CIITA 
FigUre 7 | effect of overexpressing transcription factor e2F1. Human blood monocytes differentiated for 4 days were infected with a recombinant adenovirus 
overexpressing transcription factor E2F1 or control destabilized, enhanced green fluorescent protein at 5 × 107 plaque forming units/ml for 20 h. IFN-γ or 
interleukin-4 (IL-4) were then added for 18 h in fresh medium. (a) Overexpression of E2F1 protein was determined using Western blotting. (B) Levels of Cyclin E 
mRNA or (c) proliferating cell nuclear antigen mRNA were quantified using RT-qPCR. Concentrations of mRNA for (D) AURKB, (e) ESCO2, (F) SUV39H1, and (g) 
WHSC1 are expressed relative to untreated Ad:control. p Values were calculated using ANOVA with Student–Newman–Keuls post-test. *indicates p < 0.05, 
**indicates p < 0.01, ***indicates p < 0.001, compared with Ad:control #indicates p < 0.05 compared with Ad:control + IL-4 and AdE2F1 alone. Data are presented 
as the mean ± SEM, n = 4 blood donors.
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to be upregulated to a lesser extent by IL-4, and both effects were 
independent of cell proliferation. Upregulation of NCOA1 selec-
tively by IFN-γ most likely enhances the effects CIITA (52, 53) 
but downregulation of KAT2A seems paradoxical. However, this 
might also enhance the action of IFN-γ by decreasing acetylation 
and potentiating the functions of IRFs (54). The HAT, ESCO2, 
was also downregulated by IFN-γ or IL-4, although from our 
data this appeared to be mainly the consequence of the inhibi-
tion of cell proliferation. As its full name “Establishment of Sister 
Chromatid Cohesion N-Acetyltransferase” implies, ESCO2 has a 
known role in mitosis (30). It functions as part of the cohesion 
complex and its mutation leads to the cohesinopathy, Roberts 
syndrome (55). However, cohesin (and perhaps therefore 
ESCO2) has also been ascribed a wider role in gene transcrip-
tion (56–58) and ESCO2 participates in Notch signaling (59), 
observations that might have implications for proliferating 
macrophages, although this remains to be investigated. Overall, 
our results imply that treatment with IFN-γ has the ability to 
both increase and decrease activity of specific HATs, thereby 
increasing or decreasing expression of different genes. In future 
experiments, beyond the present scope, it will be interesting to 
investigate the effects of manipulating levels of the HATs we 
have identified as up- or downregulated on both positive and 
negative transcriptional responses to IFN-γ. Recent data from 
the group of de Winther and colleagues showed, for example, 
that IFN-γ treatment specifically altered the acetylation status 
of the promoters of two downregulated genes, Il1b and Il6, in 
mouse macrophages (60), although the role of specific HATs 
and HDACs in these changes was not defined. We did not 
detect effects of IFN-γ or IL-4 on mRNA expression of any of 
the HDACs-1 to -11 that were included in our RT-qPCR screen. 
However, other mechanisms including changes in recruitment 
and activation of HATs and HDACs at specific promoters also 
contributes to acetylation status (61).
FigUre 8 | effect of KDM6 inhibitor, gsK-J4, on the transcriptome of iFn-γ or interleukin-4 (il-4) stimulated macrophages. Human blood monocytes 
differentiated for 4 days were pre-treated with 60 µM GSK-J4 or vehicle (DMSO) for 0.5 h and were then treated with either 100 ng/mL of IFN-γ or 10 ng/mL of IL-4 
for further 6 h. Purified RNA samples (n = 4 donors) were analyzed on the Illumina Human HT-12v4 microarray or by standard RT-qPCR. Venn diagrams 
summarizing changes in response to (a) GSK-J4 ± IFN-γ or (B) GSK-J4 ± IL-4. Heat maps of 10 genes inhibited by GSK-J4 more than twofold that were 
upregulated by (c) IFN-γ or (D) IL-4 [the scale is log(fold change)]. Validation of selected changes in response to (e) GSK-J4 ± IFN-γ or (F) GSK-J4 ± IL-4 using 
RT-qPCR. Data are presented as the mean ± SEM for n = 4 blood donors. **indicates p < 0.01, ***indicates p < 0.001 vs IFN-γ or IL-4 alone.
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Histone methyl transferases (HMTs) and lysine de-methylases 
(KDMs) can be stimulatory or inhibitory to transcription depend-
ing on the site and degree of methylation that is optimal (62). For 
example, H3K4 methylation has important consequences for both 
enhancer and promoter activity of macrophage specific genes 
(63). Mono and di-methylation appear permissive for enhancers 
but tri-methylation for promoters of LPS-sensitive genes (61). 
A previous study on human macrophages stimulated with LPS 
and IFN-γ (64) showed increased H3K4 methylation associ-
ated with increased expression of the HMT, myeloid lymphoid 
TaBle 4 | The most significantly enriched Kegg pathways of iFn-γ-stimulated gsK-J4 inhibited genes.
Kegg Kegg pathway genes in pathway % of genes in pathway p-Value Fold enrichment
hsa04062 Chemokine signaling pathway 8 4.73 0.00 3.29
hsa04672 Intestinal immune network for IgA production 4 2.36 0.02 6.28
hsa04630 Jak-STAT signaling pathway 6 3.55 0.04 2.98
KEGG pathway analysis was performed by using the DAVID public database (https://david.ncifcrf.gov/).
TaBle 3 | The most significantly enriched gene Ontology enrichment (gOe) terms of iFn-γ-stimulated gsK-J4-inhibited genes.
gOe Term description genes in term % of genes in term p-Value Fold enrichment
GO:0006955 Immune response 32 18.9 4.90E−13 4.71
GO:0009615 Response to virus 15 8.87 2.60E−12 13.99
GO:0006952 Defense response 25 14.79 5.20E−09 4.13
GO:0002697 Regulation of immune effector process 11 6.50 5.00E−08 11.07
GO:0002821 Positive regulation of adaptive immune response 7 4.14 4.60E−07 23.73
GO:0002684 Positive regulation of immune system process 14 8.28 5.60E−07 5.98
GO:0048584 Positive regulation of response to stimulus 13 7.69 3.30E−06 5.60
GO:0050865 Regulation of cell activation 11 6.50 8.10E−06 6.39
GO:0001817 Regulation of cytokine production 11 6.50 1.10E−05 6.18
GO:0002694 Regulation of leukocyte activation 10 5.91 3.50E−05 6.12
GOE analysis was performed by using the DAVID public database (https://david.ncifcrf.gov/).
13
Yıldırım-Buharalıog˘lu et al. Epigenetic Modifiers in Human Macrophages
Frontiers in Immunology | www.frontiersin.org February 2017 | Volume 8 | Article 92
leukemia (MLL). Given that we did not see any change in MLL 
expression with IFN-γ alone (absent from Table 2), it is possible 
that this is an effect of LPS, although this requires verification. 
In our study, the HMTs, PRMT7, SETD6, and SMYD3, were 
downregulated after priming by IFN-γ alone, independently of 
inhibition of proliferation. PRMT7 is a member of the PRMT 
histone arginine methylases, whereas SETD6 and SMYD3 are 
lysine methyl transferases. PRMT7 upregulates expression of 
metalloproteinase-9 (MMP-9) (65) in breast carcinoma cells 
but its role in macrophages is unknown. The related PRMT4 
promotes major histocompatibility II (MHCII) gene expression 
(52). SETD6 activity has been linked to repression of the nuclear 
factor κB (NF-κB) system (66, 67) and upregulation of estrogen-
responsive genes (68) in other cell types but there appears to have 
been very little previous work in mouse or human macrophages 
beyond demonstrating its presence preferentially in alternatively 
activated human macrophages, consistent with our results (64). 
SMYD3 di- and tri-methylates H3K4 residues (62). Although 
not an S-phase gene, SMYD3 has been identified as essential for 
cancer cell proliferation (69). It also plays a role in rescue from 
senescence (70), estrogen response (71), and MMP-9 induction 
(72) in various cancer cell lines. SMYD3 is also little studied 
in macrophages, although a previous study demonstrated its 
downregulation by a combination of LPS and IFN-γ, which is 
consistent with our findings (64).
In addition, the HMTs, SUV39H1, and WHSC1, were down-
regulated by IFN-γ or IL-4, at least in part, as a consequence of 
cell cycle arrest. Since SUV39H1 methylates H3K9 and places a 
repressive mark (62), it is predicted to reduce transcription of 
susceptible genes. Interestingly, one of the genes decreased by 
SUV39H1 in macrophages is p21waf1 (73), the cyclin-dependent 
kinase inhibitor that is responsible for inhibition of prolifera-
tion by IFN-γ or IL-4 (34, 35). Conversely, expression of p21waf1 
indirectly downregulates SUV39H1, which implies a mutual 
feedback mechanism that presumably fine tunes the rate of 
proliferation. WHSC1 is a candidate gene implicated in Wolf-
Hirschhorn syndrome, which is caused by deletions within 
the chromosome 4p16.3 region (74, 75). It has the ability to 
methylate several lysine residues in H3 and H4 (76) and could, 
therefore, act as a transcriptional activator or repressor. It has 
been ascribed a variety of functions, including in replicative 
DNA repair (33), which implies a role in S phase, but also in 
sustaining NF-κB pathway activity in tumors (77), which sug-
gests activity may be present in other phases of the cell cycle. 
So far, there appears to be no knowledge regarding its role in 
macrophages.
We chose to prioritize the lysine demethylase, KDM6B, for 
study in greater detail because it removes repressive H3K27Me3 
marks and is, therefore, a putative transcriptional activator. 
It is also amenable to selective pharmacological inhibition, 
which would lead to downregulation of target gene expres-
sion. Furthermore, KDM6B has been previously implicated 
in macrophage polarization by either bacterial LPS or IL-4, 
depending on the source of macrophages investigated. For 
example, KDM6B is upregulated in response to bacterial LPS 
in both mouse (78) and human (39) macrophages; and as many 
as 70% of LPS responsive genes in mouse macrophages recruit 
KDM6B to their promoters (15). This does not always lead to 
H3K27 demethylation (15) but KDM6A and B nevertheless 
act redundantly to potentiate responses to LPS in human mac-
rophages (39). Other work in mouse macrophages showed that 
KDM6B can be upregulated by IL-4 in a STAT-6-dependent 
manner and that it is essential for IL-4 induced polarization 
in vitro and in response to certain kinds of parasitic infection 
in vivo (14, 17). However, no previous study has investigated 
the role of KDM6B on both pro-inflammatory and anti-inflam-
matory polarization in the same preparation of macrophages. 
Our transcriptomic study demonstrated for the first time that 
TaBle 5 | genes significantly upregulated by iFn-γ or interleukin-4 (il-4) and most downregulated by gsKJ-4.
gene iFn-γ + DMsO vs DMsO iFn-γ + gsK-J4 vs 
iFn-γ + DMsO
gene il-4 + DMsO vs DMsO il-4 + gsK-J4 vs 
il-4 + DMsO
CCL7 8.66 −4.33 CD209 3.53 −2.2
CCL8 82.8 −3.6 C20orf123 1.99 −2.07
KIAA1618 4.1 −2.71 RGS16 1.46 −1.81
FGL2 2.82 −2.59 PALLD 5.44 −1.59
AIM2 6.4 −2.37 SUCNR1 2.55 −1.49
IFI44L 5.53 −2.28 C17orf87 3.91 −1.45
GIMAP4 2.42 −2.24 PIK3CD 1.28 −1.41
GIMAP8 2.13 −2.24 IL21R 1.55 −1.4
IDO1 43.61 −2.19 MID1IP1 1.59 −1.38
VAMP5 12.01 −2.09 OTUD6B 1.32 −1.37
MX2 2.92 −2.08 DAAM1 1.64 −1.36
ST3GAL5 1.36 −2.05 PLEKHF2 1.3 −1.32
CBX6 1.86 −2 HOPX 1.72 −1.3
KCNJ2 1.75 −1.934 METTL7A 1.26 −1.28
GIMAP7 2.6 −1.933 PIK3R6 1.42 −1.28
FST 2.34 −1.92 LOC729222 1.37 −1.27
ANKRD22 7.6 −1.9 PLA2G4A 1.23 −1.26
TNFSF10 7.45 −1.89 PPFIBP1 1.25 −1.24
PPP2RB 2.42 −1.87 CISH 2.66 −1.22
IFI44L 3.64 −1.78 C14orf149 1.22 −1.21
GIMAP6 1.8 −1.77 IL1RAP 1.33 −1.19
ISG15 2.7 −1.71 LOC100129269 1.54 −1.19
GBP1 17.95 −1.7 EFNA1 1.75 −1.19
P2RY14 3.47 −1.69 PHOSPHO1 1.16 −1.16
F3 3.06 −1.65 TMEM39B 1.16 −1.15
ENPP2 2.32 −1.65 PBX2 1.28 −1.14
GIMAP5 2.2 −1.64 EXOSC4 1.14 −1.14
STAMBPL1 4.13 −1.6376 LOC650919 1.17 −1.13
APOBEC3G 2.19 −1.6374
STAT1 5.19 −1.63
CD97 1.79 −1.62
LOC400759 7.91 −1.61
ARID5B 2.5 −1.61
C17orf87 2.06 −1.59
GBP2 6.61 −1.58
UGDH 3.03 −1.57
LOC728855 3 −1.56
ASAP2 1.31 −1.554
TMEM194A 2.62 −1.551
Four-day human monocyte-derived macrophages were treated with IFN-γ or IL-4 in the presence of DMSO vehicle or 60 µM GSK-J4 with DMSO alone as control. Fold changes 
in mRNA expression from the Illumina HumanHT-12 v4 microarray were calculated using GeneSpring. p Values calculated using the Benjamini–Hochberg false discovery rate for 
multiple testing correction were in all cases <0.05 (n = 4 separate donors).
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KDM6A and B play a part in polarization by IFN-γ, although 
a smaller proportion of genes (approximately 20%) appear to 
be affected than for responses to LPS (39). Likewise, KDM6B 
modulates some IL-4 polarization genes alone or redundantly 
with KDM6A in human macrophages but this seems to be a 
much small proportion (11%) than in mouse macrophages 
(14, 17). The finding that KDM6A and B acted redundantly 
for some processes is consistent with the previous study on 
LPS (39).
implications
Our studies significantly expand knowledge of the expression 
changes in epigenetic regulators during polarization of human 
macrophages. Upregulation or downregulation of genes does not 
necessarily imply that these will be the only enzymes that play a 
major role in responses to IFN-γ or IL-4. However, the previous 
literature on CIITA and NCOA1 together with our new results 
with KDM6B illustrates the importance of upregulated genes. 
Importantly, we identify several changes that are independent of 
FigUre 9 | effect of shrna silencing of KDM6a and KDM6B. Human blood monocytes differentiated for 4 days were infected with 2 × 108 pfu/ml of each 
individual shRNA adenovirus for 72 h and were then treated with no addition, 100 ng/mL of IFN-γ, or 10 ng/mL of interleukin-4 (IL-4) for further 6 h. (a) The levels of 
mRNAs for KDM6A, KDM6B, or housekeeping gene, 36B4, were measured in cells infected with adenovirus expressing shKDM6A or shKDM6B were normalized 
against those with shLuciferase (shLUC) as control. (B) Protein of levels KDM6A and housekeeping gene GAPDH under the same conditions. (c) The effects of 
shKDM6A, shKDM6B, individually, or together on mRNA levels of genes upregulated by IFN-γ or IL-4. Data are presented as the mean ± SEM relative to shLUC for 
n = 6 blood donors. *indicates p < 0.05, **indicates p < 0.01 vs shLUC.
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inhibition of proliferation, a complicating factor that appears to 
have been overlooked in previous studies. However, those changes 
partly dependent of proliferation may also be of significance. 
Indeed, recent work has highlighted the importance of prolifera-
tion in replenishing populations of resident macrophages (79). 
There have also been interesting findings in models of inflam-
mation, especially atherosclerotic plaque formation (80), sug-
gesting that proliferation rather than recruitment may play the 
major role in sustaining macrophage numbers. From our data, 
proliferation has a major impact on epigenetic programing, and 
this undoubtedly influences macrophage behavior. Future work, 
beyond the present scope, should probe into the downregulated 
genes we have identified, many of which are virtually unstudied 
in macrophages. However, we recognize that mechanisms other 
than changes in expression level regulate the function of epige-
netic writers, readers and erasers at the promoters and enhancers 
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of pro- and anti-inflammatory genes (61, 81). Except in the case 
of KDM6B, the contribution that the expression changes we 
observed make to epigenetic regulation in macrophages remains 
to be established.
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